Michael C. Campbell to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Michael C. Campbell has written about Dose-Response Relationship, Drug.
Connection Strength
0.103
-
Liu W, Mousa AAK, Hopkins AM, Wu YF, Thu KL, Campbell M, Lees SJ, Ramachandran R, Hou J. Lysophosphatidic Acid Receptor 1 (LPA1) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. ChemMedChem. 2024 Aug 19; 19(16):e202400013.
Score: 0.043
-
Weaver MJ, Stump S, Campbell MJ, Backos DS, Li C, Reigan P, Adams E, Beall HD, Natale NR. 10-N-heterocylic aryl-isoxazole-amides (AIMs) have robust anti-tumor activity against breast and brain cancer cell lines and useful fluorescence properties. Bioorg Med Chem. 2020 11 15; 28(22):115781.
Score: 0.034
-
Heller S, White D, Lee E, Lawton J, Pollard D, Waugh N, Amiel S, Barnard K, Beckwith A, Brennan A, Campbell M, Cooper C, Dimairo M, Dixon S, Elliott J, Evans M, Green F, Hackney G, Hammond P, Hallowell N, Jaap A, Kennon B, Kirkham J, Lindsay R, Mansell P, Papaioannou D, Rankin D, Royle P, Smithson WH, Taylor C. A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. Health Technol Assess. 2017 04; 21(20):1-278.
Score: 0.026